Tags

Type your tag names separated by a space and hit enter

Evaluation of Eudragit RS-PO and Ethocel 100 matrices for the controlled release of lobenzarit disodium.
Drug Dev Ind Pharm. 1999 Feb; 25(2):229-33.DD

Abstract

Lobenzarit disodium is a drug for the treatment of rheumatoid arthritis. In this work, inert matrix tablets of lobenzarit disodium were prepared by direct compression using Ethocel 100 and Eudragit RS-PO as polymeric materials in different ratios. The obtained powder mixtures and tablets were evaluated from the rheological and technological points of view. The dissolution test was performed to evaluate the in vitro release kinetic of the matrices. The obtained dissolution profiles demonstrated that the matrices containing Eudragit RS-PO showed a slower release rate and therefore were more suitable for controlling the release of drug. The fit to the Higuchi model indicates that the drug release mechanism from these matrices was controlled by the diffusion step.

Links

Publisher Full Text

Authors+Show Affiliations

Boza A
Department of Chemical Synthesis, Center of Pharmaceutical Chemistry, La Habana, Cuba.
Caraballo I
No affiliation info available
Alvarez-Fuentes J
No affiliation info available
Rabasco AM
No affiliation info available

MeSH

Acrylic ResinsAnti-Inflammatory Agents, Non-SteroidalCelluloseChemistry, PharmaceuticalDelayed-Action PreparationsDrug Delivery SystemsExcipientsPolymersPolymethacrylic AcidsPowdersRheologyTabletsortho-Aminobenzoates

Pub Type(s)

Journal Article

Language

eng

PubMed ID

10065357

Citation

Boza, A, et al. "Evaluation of Eudragit RS-PO and Ethocel 100 Matrices for the Controlled Release of Lobenzarit Disodium." Drug Development and Industrial Pharmacy, vol. 25, no. 2, 1999, pp. 229-33.
Boza A, Caraballo I, Alvarez-Fuentes J, et al. Evaluation of Eudragit RS-PO and Ethocel 100 matrices for the controlled release of lobenzarit disodium. Drug Dev Ind Pharm. 1999;25(2):229-33.
Boza, A., Caraballo, I., Alvarez-Fuentes, J., & Rabasco, A. M. (1999). Evaluation of Eudragit RS-PO and Ethocel 100 matrices for the controlled release of lobenzarit disodium. Drug Development and Industrial Pharmacy, 25(2), 229-33.
Boza A, et al. Evaluation of Eudragit RS-PO and Ethocel 100 Matrices for the Controlled Release of Lobenzarit Disodium. Drug Dev Ind Pharm. 1999;25(2):229-33. PubMed PMID: 10065357.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of Eudragit RS-PO and Ethocel 100 matrices for the controlled release of lobenzarit disodium. AU - Boza,A, AU - Caraballo,I, AU - Alvarez-Fuentes,J, AU - Rabasco,A M, PY - 1999/3/5/pubmed PY - 1999/3/5/medline PY - 1999/3/5/entrez SP - 229 EP - 33 JF - Drug development and industrial pharmacy JO - Drug Dev Ind Pharm VL - 25 IS - 2 N2 - Lobenzarit disodium is a drug for the treatment of rheumatoid arthritis. In this work, inert matrix tablets of lobenzarit disodium were prepared by direct compression using Ethocel 100 and Eudragit RS-PO as polymeric materials in different ratios. The obtained powder mixtures and tablets were evaluated from the rheological and technological points of view. The dissolution test was performed to evaluate the in vitro release kinetic of the matrices. The obtained dissolution profiles demonstrated that the matrices containing Eudragit RS-PO showed a slower release rate and therefore were more suitable for controlling the release of drug. The fit to the Higuchi model indicates that the drug release mechanism from these matrices was controlled by the diffusion step. SN - 0363-9045 UR - https://www.unboundmedicine.com/medline/citation/10065357/Evaluation_of_Eudragit_RS_PO_and_Ethocel_100_matrices_for_the_controlled_release_of_lobenzarit_disodium_ L2 - https://www.tandfonline.com/doi/full/10.1081/ddc-100102164 DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓5]

Related Citations

More